Despite the use of rituximab as a substantial treatment for Diffuse Large B-Cell Lymphoma (DLBCL), the survival rate remains low due to high incidences of relapse. Several predictive factors for relapse have been investigated however, still expensive and not applicable. Lymphocyte-monocyte ratio (LMR) reported as a predictor factor for treatment responses of DLBCL patients.The aims of this study to know the profile of predictor factors include age, LDH, Ann Arbor stage, extranodal involvement and lymphocyte-monocyte ratio (LMR), with the treatment response of LNH type Diffuse Large B-Cell Lymphoma (DLBCL) patients in dr. Soetomo Surabaya.A retrospective observational descriptive study of 203 subjects undergoing R-CHOP chemotherapy during 2015-2017. Predictor variables were age, LDH, Ann Arbor stage, extranodal involvement and LMR. Elderly > 60 more unresponsive to chemotherapy 24 (46,2%) vs 28 (19%), high LDH more unresponsive 49 (94,2%) vs 3 (5, 8%). Ann Arbor stage III-IV more responsive to chemo than stage I-II, 24 (15,9%) vs 127 (84,155). In LMR< 2,6 subgroup, 84 (55,6%) subjects showed response to chemotherapy, while in LMR < 2,6 subgroup only 67 (44,4%) subgroups showed response. The conclusion of this study are subjects ≥60 years old, high LDH ≥200 U/l, early stage of disease, extranodal involvement and LMR<2.6 had a higher risk of unresponsiveness to chemotherapy.
|Number of pages||7|
|Journal||Journal of International Dental and Medical Research|
|Publication status||Published - 29 Jun 2020|
- predictive factors
- therapeutic response